Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,682 INR | +2.59% | +2.99% | +12.85% |
02/02 | Transcript : Poly Medicure Limited, Q3 2024 Earnings Call, Feb 02, 2024 | |
31/01 | Poly Medicure Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 63.24 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+12.85% | 1.94B | C | ||
-3.79% | 184B | C+ | ||
-0.84% | 108B | C | ||
-3.75% | 67.82B | A | ||
+3.45% | 51.05B | B- | ||
+9.04% | 44.67B | B- | ||
+3.40% | 41.78B | B+ | ||
+3.21% | 26.78B | B | ||
+3.66% | 26.59B | A- | ||
+15.23% | 25.86B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- POLYMED Stock
- Ratings Poly Medicure Limited